2011 Fiscal Year Final Research Report
Development of novel oncofetal antigen targeting immunotherapy for refractory ovarian carcinoma
| Project/Area Number |
21592127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
SHIBATA Kiyosumi 名古屋大学, 大学院・医学系研究科, 准教授 (90335026)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIKKAWA Fumitaka 名古屋大学, 大学院・医学系研究科, 教授 (40224985)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | 難治性卵巣がん / 免疫療法 / Glypican-3 / ペプチドワクチン / 臨床試験 |
|---|
| Research Abstract |
We started a phase II clinical trial of HLA-A24 and A2 restrictive Glypican-3(GPC3) peptide vaccine for clear cell carcinoma of ovary as one of the immunotherapy for refractory ovarian carcinoma. We confirmed the safety of the vaccine and GPC3 specific CTL by Ex vivo IFN
|
Research Products
(5 results)
-
-
[Journal Article] Mismatched human leukocyte antigen class II-restricted CD8. cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation2011
Author(s)
Hirosawa T, Torikai H, Yanagisawa M, Kamei M, Imahashi N, Demachi-Okamura A, Tanimoto M, Shiraishi K, Ito M, Miyamura K, Shibata K, Kikkawa F, Morishima Y, Takahashi T, Emi N, Kuzushima K, Akatsuka Y
-
Journal Title
Cancer Sci
Volume: 102(7)
Pages: 1281-1286
Peer Reviewed
-
-
-
